Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial

被引:12
|
作者
Huang, Yu [1 ]
Chen, Jinnan [1 ]
Ding, Zhaohui [1 ]
Chen, Xi [1 ]
Liang, Xiao [1 ]
Zeng, Xin [2 ]
Xu, Fei [2 ]
Han, Yuehua [3 ]
Lu, Hong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab Di, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China
[3] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Minocycline; Tetracycline; Rescue therapy; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; AMOXICILLIN; METRONIDAZOLE; ERADICATION; DOXYCYCLINE; INFECTION; EFFICACY; SAFETY; SUSCEPTIBILITY;
D O I
10.1007/s00535-023-01991-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundTo compare the efficacy and tolerability of minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) rescue treatment.MethodsThis study was a multi-center, randomized-controlled, non-inferiority trial. Refractory H. pylori-infected subjects with multiple treatment-failure were randomly (1:1) allocated to receive 14-day therapy with esomeprazole 20 mg b.i.d, bismuth 220 mg b.i.d, plus metronidazole 400 mg q.i.d and minocycline 100 mg b.i.d (minocycline group) or tetracycline 500 mg q.i.d (tetracycline group). Primary outcome was H. pylori eradication rate evaluated by C-13-urea breath test at least 6 weeks after the end of treatment. Antibiotic resistance was determined using E test method.ResultsThree hundred and sixty-eight subjects were randomized. The eradication rates in minocycline group and tetracycline group were 88.0% (162/184, 95% CI 83.3-92.8%) and 88.6% (163/184, 95% CI 83.9-93.2%) in intention-to-treat analysis, 98.0% (149/152, 95% CI 95.8-100%) and 97.4% (150/154, 95% CI 94.9-99.9%) in per-protocol analysis, 93.1% (162/174, 95% CI 89.3-96.9%) and 93.1% (163/175, 95% CI 89.4-96.9%) in modified intention-to-treat analysis. Minocycline, tetracycline and metronidazole resistance rates were 0.7%, 1.4% and 89.6%, respectively. Non-inferiority of minocycline was confirmed (P < 0.025). Metronidazole resistance did not affect the efficacy of either therapy. The two therapies exhibited comparable frequencies of adverse events (55.4% vs. 53.3%); almost half of them were mild. Dizziness was the most common adverse events in the minocycline group.ConclusionsMinocycline can be an alternative for tetracycline in bismuth-containing quadruple therapy for H. pylori empirical rescue treatment, irrespective of metronidazole resistance. However, relatively high incidence of adverse events in both regimens should be emphasized.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 50 条
  • [31] Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
    Yang, Jing
    Zhang, Yi
    Fan, Ling
    Zhu, Yang-Jie
    Wang, Ting-Yi
    Wang, Xing-Wei
    Chen, Dong-Feng
    Lan, Chun-Hui
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (03) : 437 - 445
  • [32] Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial
    Ding, Yu-Ming
    Zhang, Qiu-Mei
    Li, Rui-Li
    Han, Zhong-Xue
    Zhao, Qing
    Xu, Li-Dong
    Wang, Ke-Yu
    Nan, Xue-Ping
    Duan, Miao
    Zeng, Shu-Yan
    Kong, Qing-Zhou
    Wang, Hui
    Wu, Xiao-Qi
    Zhang, Ning
    Li, Yan-Qing
    Zuo, Xiu-Li
    Li, Yue-Yue
    HELICOBACTER, 2024, 29 (04)
  • [33] High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis
    Wang, Hui
    Kong, Qing Zhou
    Li, Yue Yue
    Yang, Xiao Yun
    Zuo, Xiu Li
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (03) : 163 - 175
  • [34] Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy
    Chung, Jun-Won
    Lee, Jeong Hoon
    Jung, Hwoon-Yong
    Yun, Sung-Cheol
    Oh, Tae-Hoon
    Choi, Kee Don
    Song, Ho June
    Lee, Gin Hyug
    Kim, Jin-Ho
    HELICOBACTER, 2011, 16 (04) : 289 - 294
  • [35] Single-capsule bismuth-based quadruple therapy as a rescue therapy for Helicobacter pylori eradication
    Correia, Catarina
    Almeida, Nuno
    Leal, Carina
    Branquinho, Diogo
    Fernandes, Alexandra
    Gravito-Soares, Elisa
    Calhau, Carlos
    Bastos, Isabel
    Vasconcelos, Helena
    Figueiredo, Pedro
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (03) : 227 - 231
  • [36] Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study
    Kim, Ji Yoon
    Kim, Sang Gyun
    Cho, Soo-Jeong
    MEDICINE, 2023, 102 (48) : E36310
  • [37] Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
    Huh, Ki Young
    Chung, Hyewon
    Kim, Yu Kyong
    Lee, SeungHwan
    Bhatia, Siddharth
    Takanami, Yohei
    Nakaya, Ryou
    Yu, Kyung-Sang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 138 - 144
  • [38] Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
    Ouyang, Yaobin
    Zhang, Wenjing
    He, Chen
    Zhu, Yin
    Lu, Nonghua
    Hu, Yi
    FRONTIERS IN MEDICINE, 2022, 9
  • [39] High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection - A review of the strengths, weaknesses, and proposed solutions
    Hu, Chi-Tan
    TZU CHI MEDICAL JOURNAL, 2022, 34 (03): : 303 - 309
  • [40] Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
    Lee, Ju Yup
    Kim, Nayoung
    Park, Kyung Sik
    Kim, Hyun Jin
    Park, Seon Mee
    Baik, Gwang Ho
    Shim, Ki-Nam
    Oh, Jung Hwan
    Choi, Suck Chei
    Kim, Sung Eun
    Kim, Won Hee
    Park, Seon-Young
    Kim, Gwang Ha
    Lee, Bong Eun
    Jo, Yunju
    Hong, Su Jin
    BMC GASTROENTEROLOGY, 2016, 16